<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006251</url>
  </required_header>
  <id_info>
    <org_study_id>1533.00</org_study_id>
    <secondary_id>NCI-2013-01634</secondary_id>
    <secondary_id>1533.00</secondary_id>
    <secondary_id>P01CA078902</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00006251</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer</brief_title>
  <official_title>Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and donor&#xD;
      stem cell transplant followed by cyclosporine, mycophenolate mofetil, and donor lymphocyte&#xD;
      infusion in treating patients with hematopoietic cancer. Giving low doses of chemotherapy,&#xD;
      such as fludarabine phosphate, and total body irradiation (TBI) before a donor peripheral&#xD;
      blood stem cell transplant helps stop the growth of cancer cells. It may also keep the&#xD;
      patient's immune response from rejecting the donor's stem cells. The donated stem cells may&#xD;
      replace the patient's immune cells and help destroy any remaining cancer cells&#xD;
      (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte&#xD;
      infusion) after the transplant may help increase this effect. Sometimes the transplanted&#xD;
      cells from a donor can also make an immune response against the body's normal cells. Giving&#xD;
      cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the risk of graft rejection associated with the addition of fludarabine&#xD;
      (fludarabine phosphate) to a non-myeloablative conditioning regimen for patients with&#xD;
      malignant diseases treatable by allogeneic stem cell transplantation and compare this rate to&#xD;
      that observed among patients previously treated without fludarabine.&#xD;
&#xD;
      II. To estimate the rate of grade acute II/IV graft-vs-host disease (GVHD) and chronic GVHD&#xD;
      in patients treated with low-dose total-body irradiation (TBI), fludarabine, peripheral blood&#xD;
      stem cell (PBSC) infusion and immunosuppression with cyclosporine and mycophenolate mofetil.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days - 4&#xD;
      to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous&#xD;
      transplant within 90 days prior to day 0 will not receive fludarabine phosphate.)&#xD;
&#xD;
      PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0.&#xD;
&#xD;
      IMMUNOSUPPRESSION: Patients receive cyclosporine orally (PO) twice daily (BID) on days -3 to&#xD;
      35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27.&#xD;
&#xD;
      POST TRANSPLANT DONOR LYMPHOCYTE INFUSION (DLI): Patients with stable mixed chimerism on day&#xD;
      56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without&#xD;
      a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at&#xD;
      higher cell numbers. Up to 6 DLIs may be given 65 days apart.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4, 6, 12, 18 and 24 months&#xD;
      and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of graft rejection defined as the absence of detectable peripheral blood donor T cells with the addition of fludarabine phosphate</measure>
    <time_frame>Up to day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of acute grade II/IV GVHD</measure>
    <time_frame>Up to day 90 after the last DLI</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of myelosuppression (ANC &lt; 500/ul for &gt; 2 days, platelets &lt; 20,000/ul for &gt; 2 days) after initial PBSC infusion</measure>
    <time_frame>Up to day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of malignancy to DLI</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of aplasia after DLI</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of CD3+ cells required to convert mixed to full lymphoid chimeras</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Adult Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Angioimmunoblastic T-cell Lymphoma</condition>
  <condition>Childhood Burkitt Lymphoma</condition>
  <condition>Childhood Diffuse Large Cell Lymphoma</condition>
  <condition>Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Childhood Immunoblastic Large Cell Lymphoma</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Childhood Nasal Type Extranodal NK/T-cell Lymphoma</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Cutaneous B-cell Non-Hodgkin Lymphoma</condition>
  <condition>de Novo Myelodysplastic Syndromes</condition>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Hepatosplenic T-cell Lymphoma</condition>
  <condition>Intraocular Lymphoma</condition>
  <condition>Juvenile Myelomonocytic Leukemia</condition>
  <condition>Mast Cell Leukemia</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable</condition>
  <condition>Myeloid/NK-cell Acute Leukemia</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Noncutaneous Extranodal Lymphoma</condition>
  <condition>Peripheral T-cell Lymphoma</condition>
  <condition>Post-transplant Lymphoproliferative Disorder</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Primary Systemic Amyloidosis</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Burkitt Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Mixed Cell Lymphoma</condition>
  <condition>Recurrent Adult Diffuse Small Cleaved Cell Lymphoma</condition>
  <condition>Recurrent Adult Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Immunoblastic Large Cell Lymphoma</condition>
  <condition>Recurrent Adult Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Adult T-cell Leukemia/Lymphoma</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Anaplastic Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Grade III Lymphomatoid Granulomatosis</condition>
  <condition>Recurrent Childhood Large Cell Lymphoma</condition>
  <condition>Recurrent Childhood Lymphoblastic Lymphoma</condition>
  <condition>Recurrent Childhood Small Noncleaved Cell Lymphoma</condition>
  <condition>Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Mycosis Fungoides/Sezary Syndrome</condition>
  <condition>Recurrent Renal Cell Cancer</condition>
  <condition>Recurrent Small Lymphocytic Lymphoma</condition>
  <condition>Recurrent/Refractory Childhood Hodgkin Lymphoma</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Hairy Cell Leukemia</condition>
  <condition>Refractory Multiple Myeloma</condition>
  <condition>Small Intestine Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <condition>Stage II Multiple Myeloma</condition>
  <condition>Stage III Multiple Myeloma</condition>
  <condition>T-cell Large Granular Lymphocyte Leukemia</condition>
  <condition>Testicular Lymphoma</condition>
  <condition>Waldenstr√∂m Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.)&#xD;
PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0.&#xD;
IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27.&#xD;
POST TRANSPLANT DLI: Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic PBSC transplant</description>
    <arm_group_label>Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>donor lymphocytes</intervention_name>
    <description>Undergo DLI</description>
    <arm_group_label>Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo allogeneic PBSC transplant</description>
    <arm_group_label>Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged &gt; 49 years and &lt; 75 years with non-Hodgkin lymphoma (NHL), chronic&#xD;
             lymphocytic leukemia (CLL) and multiple myeloma who are not eligible for a curative&#xD;
             autologous transplantation or who have failed prior autologous transplantation;&#xD;
             patients with NHL and CLL must have failed prior therapy with an alkylating agent&#xD;
             and/or fludarabine, or be at high risk of relapse; patients with multiple myeloma must&#xD;
             have stage II or III disease and received prior chemotherapy&#xD;
&#xD;
          -  Patients &lt; 50 years of age with NHL, CLL or multiple myeloma at high risk of regimen&#xD;
             related toxicity through prior autologous transplant or through pre-existing medical&#xD;
             conditions&#xD;
&#xD;
          -  Patients &lt; 75 years of age with other malignant diseases treatable by allogeneic bone&#xD;
             marrow transplant (BMT) whom through pre-existing chronic disease affecting kidneys,&#xD;
             liver, lungs, and heart are considered to be at high risk for regimen related toxicity&#xD;
             using standard high dose regimens; the following diseases are the likely candidates:&#xD;
&#xD;
               -  Myelodysplastic syndromes&#xD;
&#xD;
               -  Myeloproliferative syndromes&#xD;
&#xD;
               -  Acute Leukemia with &lt; 10% blasts&#xD;
&#xD;
               -  Amyloidosis&#xD;
&#xD;
               -  Hodgkin's disease&#xD;
&#xD;
               -  Renal cell carcinoma&#xD;
&#xD;
          -  Patients with other malignancies declining standard allografts may be approved for&#xD;
             transplant following presentation and approval by the Fred Hutchinson Cancer Research&#xD;
             Center (FHCRC) chimerism group&#xD;
&#xD;
          -  DONOR:&#xD;
&#xD;
               -  Human leukocyte antigen (HLA) genotypically or phenotypically identical related&#xD;
                  donor&#xD;
&#xD;
               -  Donor must consent to granulocyte colony-stimulating factor (G-CSF)&#xD;
                  administration and leukopheresis&#xD;
&#xD;
               -  Donor must have adequate veins for leukopheresis or agree to placement of central&#xD;
                  venous catheter (femoral, subclavian)&#xD;
&#xD;
               -  Age &lt; 75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligible for a high-priority curative autologous transplant&#xD;
&#xD;
          -  Patients with rapidly progressive aggressive NHL unless in minimal disease state&#xD;
&#xD;
          -  Active central nervous system (CNS) involvement with disease&#xD;
&#xD;
          -  Fertile men or women unwilling to use contraceptive techniques during and for 12&#xD;
             months following treatment&#xD;
&#xD;
          -  Females who are pregnant&#xD;
&#xD;
          -  Patients who are human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 40%&#xD;
&#xD;
          -  Severe defects in pulmonary function testing (defects are currently categorized as&#xD;
             mild, moderate and severe) as defined by the pulmonary consultant, or receiving&#xD;
             supplementary continuous oxygen&#xD;
&#xD;
          -  Total bilirubin &gt; 2 x the upper limit of normal&#xD;
&#xD;
          -  Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic&#xD;
             transaminase (SGOT) 4 x the upper limit of normal&#xD;
&#xD;
          -  Karnofsky score &lt; 50&#xD;
&#xD;
          -  Patients with poorly controlled hypertension&#xD;
&#xD;
          -  Patients with renal failure are eligible, however patients with renal compromise&#xD;
             (serum creatinine greater than 2.0) will likely have further compromise in renal&#xD;
             function and may require hemodialysis (which may be permanent) due to the need to&#xD;
             maintain adequate serum cyclosporine levels&#xD;
&#xD;
          -  DONOR:&#xD;
&#xD;
               -  Identical twin&#xD;
&#xD;
               -  Age less than 12 years&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Infection with HIV&#xD;
&#xD;
               -  Inability to achieve adequate venous access&#xD;
&#xD;
               -  Known allergy to G-CSF&#xD;
&#xD;
               -  Current serious systemic illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Maloney</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>June 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2004</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Hairy Cell</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Leukemia, Mast-Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

